Ribavirin (GMP)

Ribavirin (GMP) is Ribavirin (HY-B0434) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities. In Vitro: Treatment of LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin GMP (ICN-1229) induces reduction of NO₂ levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin GMP (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia^[3].
Ribavirin GMP (ICN-1229) is active against DENV, with an EC₅₀ of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin GMP (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication^[4].
Ribavirin (20 μM, 7 d) inhibits hepatitis C virus (HCV) replication in Functional hepatocyte-like cells which developed from hiPSC^[6].
Ribavirin (1, 10, 25 μg/ml, 72 h) attenuates ZIKV-induced cell apoptosis in hNPCs via modulation of apoptosis-regulatory genes and promotes survival signaling via the PI3K/AKT pathway^[7].
In Vivo: ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin GMP (ICN-1229) (p<0.01). JAT, interferon or Ribavirin GMP alone with CCl₄, livers appear to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin GMP (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin GMP (ICN-1229), and JAT, the expression level of p53 is markedly reduced^[1].
Ribavirin GMP (ICN-1229) capsules (400 mg of Ribavirin GMP)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin GMP (ICN-1229) has strong antiviral activity only when Ribavirin GMP is combined with either IFN-α or Peg-IFN-α^[2].
Ribavirin GMP (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin GMP (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy^[4].